Common Contracts
2 similar Exclusive License Agreement contracts by Atara Biotherapeutics, Inc.
AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of June 28, 2013 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and PINTA BIOTHERAPEUTICS, INC., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 22nd, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), dated as of June 28, 2013 (the “Amendment Effective Date”), is made by and between AMGEN INC., a Delaware corporation having an address of One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and PINTA BIOTHERAPEUTICS, INC., a Delaware corporation having an address of 3260 Bayshore Blvd, Brisbane, California 94005 (“Licensee”).
